Participant Data obtained to 30Sep2015:

Baseline data: 447 6 month data: 253 Program terminated: recruitment target not met. No analysis will be provided.

The study purpose is to assess adverse events in patients with Type 2 diabetes who have newly been prescribed Forxiga for the management of glycemic control

Observational Model: Other: A post-marketing evaluation of the safety of Forxiga through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice

Inclusion Criteria:

Patients with Type 2 Diabetes who are:

• Prescribed Forxiga for glycaemic management AND
• Who have the ability to provide informed consent

Exclusion Criteria:

Patients with whom use of Forxiga is contraindicated:

• Patients with Type 1 Diabetes
• Patients with moderate to severe renal impairment [Creatinine clearance (CrCl) <60 mL/min or estimated glomerular filtration rate (eGFR) <60mL/min/1.73m²]

Additional exclusion criteria:

• Age >75 years
• Concomitant use of loop diuretics or pioglitazone
• Patients who are currently on another SGLT2 inhibitor

Patients with Type 2 Diabetes whom the Healthcare professional (HCP) would consider as suitable candidates for Forxiga treatment will be invited to participate in the program during routine clinical assessment